Latest Advanced Manufacturing News

Amaero Ltd has launched a $3 million Share Purchase Plan offering eligible shareholders in Australia and New Zealand the chance to buy new shares at $0.40 each, matching a recent placement price. The offer opens on 29 August and closes on 19 September 2025.

Advanced Braking Technology Ltd (ASX, ABV) reported a robust 25% revenue increase and 36% net profit growth for FY25, driven by international expansion and pioneering product launches in mining safety technology.

Titomic Limited reported a 22.5% increase in revenue to $9.43 million for FY2025 but saw losses soar by over 67%, highlighting ongoing financial challenges despite growth.

Tetratherix Limited advances its Tetramatrix biomaterial platform with a robust IP portfolio, scalable manufacturing, and strategic partnerships aimed at commercialising across multiple clinical franchises.

dorsaVi appoints Mathew Regan as Group CEO to spearhead commercialisation of next-gen RRAM-enabled AI and robotics technologies, aiming for global expansion.

Tetratherix Limited reports its first financial results as a listed company, revealing a $9.4 million statutory loss driven by R&D and listing costs, alongside a robust $29.3 million cash position post-IPO. The company highlights key operational milestones and outlines strategic plans to accelerate commercialisation across its innovative biomaterial platform.

Tetratherix Limited reported a $9.4 million statutory loss for FY25 amid significant R&D and operational investments, successfully listing on the ASX and progressing multiple clinical and manufacturing initiatives.

Ark Mines Ltd is fast-tracking its Sandy Mitchell rare earths project in Queensland, backed by a $4.5 million investment from the Queensland Investment Corporation and targeting production by late 2027.

IperionX secures a $12.5 million funding tranche from the U.S. Department of Defense to fast-track expansion of its Virginia titanium manufacturing capacity beyond 1,000 metric tons annually.

Actinogen Medical reports steady progress in its Alzheimer’s and depression drug trials, backed by strong funding and strategic commercial planning. Key interim data from the pivotal XanaMIA trial is expected early next year.

PWR Holdings Limited posted a 6.7% revenue decline and a 60.6% drop in net profit for FY2025, impacted by contract completions and factory relocation. Despite short-term setbacks, the company is investing heavily in new facilities, aerospace growth, and sustainability initiatives.

Amaero Ltd has secured A$50 million through a share placement and plans a further A$3 million via a Share Purchase Plan to fast-track growth initiatives aligned with U.S. defense and manufacturing re-shoring priorities.